Protalix Biotherapeutics (NYSE: PLX) revenue
Protalix Biotherapeutics reported revenue of $52.7m for fiscal 2025, 1.2% less than in fiscal 2024 ($53.4m). Since fiscal 2016 its revenue has grown by 473.4%, an average growth of 21.4% a year.
Protalix Biotherapeutics's revenue has fallen for 2 years in a row, and its best year of the last 10 was fiscal 2023. The biggest drop was in fiscal 2021, −39.0%.
Embed this chart
Copy this code into your website or blog. The chart updates with each new annual report.
Revenue by fiscal year
| Fiscal year | Revenue | Change | Operating profit | Operating margin |
|---|---|---|---|---|
| 2025 | $52.7m | −1.2% | −$5.5m | −10.4% |
| 2024 | $53.4m | −18.5% | $3.9m | 7.3% |
| 2023 | $65.5m | +37.5% | $10.5m | 16.0% |
| 2022 | $47.6m | +24.2% | −$13.0m | −27.3% |
| 2021 | $38.4m | −39.0% | −$20.5m | −53.4% |
| 2020 | $62.9m | +15.0% | $2.7m | 4.3% |
| 2019 | $54.7m | +59.7% | −$10.7m | −19.6% |
| 2018 | $34.2m | +62.4% | −$19.3m | −56.4% |
| 2017 | $21.1m | +129.1% | −$34.5m | −163.8% |
| 2016 | $9.2m | — | −$33.2m | −360.5% |
The change compares each fiscal year with the one before. Operating margin is operating profit over revenue from the same filing. Figures are in millions of US dollars, except per-share amounts.
Protalix Biotherapeutics revenue compared with its sector
By revenue for its latest fiscal year, Protalix Biotherapeutics ranks 326th of the 422 US health care companies with a page on Celsmar. The sector median grew 11.7% in its latest fiscal year; Protalix Biotherapeutics, −1.2%.
| Rank | Company | Revenue | Revenue growth |
|---|---|---|---|
| 324th | Agios Pharmaceuticals | $54.0m | 48.0% |
| 325th | Invivyd | $53.4m | 110.5% |
| 326th | Protalix Biotherapeutics | $52.7m | −1.2% |
| 327th | Ocular Therapeutix | $52.0m | −18.5% |
| 328th | Lexicon Pharmaceuticals | $49.8m | 60.2% |
Each amount is in the currency the company reports in; the rank converts them to US dollars at the 16 November 2026 exchange rate. The rest are in US health care stocks.
Questions about the revenue of Protalix Biotherapeutics
- How much revenue did Protalix Biotherapeutics make in fiscal 2025?
- Protalix Biotherapeutics reported revenue of $52.7m for fiscal 2025, compared with $53.4m in fiscal 2024.
- How much has the revenue of Protalix Biotherapeutics grown?
- Between fiscal 2016 and fiscal 2025 it went from $9.2m to $52.7m: 473.4% more, an average growth of 21.4% a year.
- What was the best year for revenue at Protalix Biotherapeutics?
- Of its last 10 fiscal years, fiscal 2023, with $65.5m.
- Where does Protalix Biotherapeutics rank in its sector by revenue?
- It ranks 326th of the 422 US health care companies with a page on Celsmar, by revenue for its latest fiscal year.
- Where do the figures for Protalix Biotherapeutics come from?
- From the annual report (Form 10-K) that Protalix Biotherapeutics files with the SEC, the US securities regulator. Each fiscal year links to its filing.
Where each figure comes from
From the annual report (Form 10-K) that Protalix Biotherapeutics files with the SEC. The filing for each fiscal year: 2025 · 2024 · 2023 · 2022 · 2021 · 2020 · 2019 · 2018 · 2017 · 2016. More on Protalix Biotherapeutics: the Protalix Biotherapeutics page · annual accounts · net income · insider transactions.
Information prepared from the accounts the company files with the regulator, for information purposes only. It is not financial advice or a recommendation to buy or sell. Updated on 12 November 2026.